STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm:
CALTX) ("Calliditas") today announced that former Head of
North America Commercial, Andrew
Udell, has been promoted to President, North America, effective
immediately.
"Andrew has been instrumental in the growth of the US operations
over the last 12 months and has done a great job of creating a
strong connection between the US and European teams throughout this
period of high growth. He is an experienced leader, and I am
delighted to continue to work with him in this new role," said CEO
Renee Aguiar-Lucander.
In his new role, Mr. Udell will oversee all of Calliditas' US
related activities, with direct reports including sales,
marketing and market access. Mr. Udell joined Calliditas in 2019
and has over 20 years of broad commercial experience in the
pharmaceutical industry, working with both established and growing
pharma companies.
"I am thrilled for the opportunity to lead and continue to work
with such a strong, talented, and rapidly growing team as we build
upon the foundation created in these last few years. It is an
exciting and critical time at Calliditas as we prepare for the
commercialization of the first potential treatment for patients
suffering with IgA nephropathy," expressed Mr.
Udell.
As previously reported, the FDA has accepted the submission
of and granted Priority Review for the New Drug Application (NDA)
for Calliditas' lead product candidate, Nefecon, setting a PDUFA
goal date of September 15, 2021.
Subject to approval by the FDA, Calliditas intends to commercialize
Nefecon for IgA nephropathy on its own in the United States.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on May
3, 2021 at 2.30 p.m.
CET.
About Calliditas
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of the autoimmune renal
disease IgA nephropathy, or IgAN, for which there is a high unmet
medical need and there are no approved treatments. Calliditas
successfully reported top line data of its global Phase 3 study in
IgAN in November of 2020 and, if approved, aims to commercialize
Nefecon in the United States on
its own and partner elsewhere. Calliditas is listed on Nasdaq
Stockholm (ticker: CALTX) and the Nasdaq Global Select Market
(ticker: CALT). Visit www.calliditas.com for further
information.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-promotes-andrew-udell-to-president--north-america,c3338764
The following files are available for download:
https://mb.cision.com/Main/16574/3338764/1411566.pdf
|
Andy Udell Promotion
Eng
|